inactivated SARS-CoV-2 Vaccine / Chinese Academy of Medical Sciences - LARVOL DELTA

Preconception COVID-19 Vaccination Reprograms Fetal Metabolism to Accelerate Intrauterine Recovery and Suppress Persistent Metabolic Memory. (PubMed, J Med Virol) - "Mothers were stratified into two groups: those fully vaccinated (inactivated COVID-19 vaccines) before conception (n = 81) and unvaccinated (n = 56)...It prevents the establishment of a detrimental "metabolic memory" effect posing potential developmental risks. These findings reveal a novel non-immune, metabolome-mediated protective mechanism of maternal vaccination, which thus supports COVID-19 vaccination for women of childbearing age."

Journal • Infectious Disease • Metabolic Disorders • Novel Coronavirus Disease • Respiratory Diseases

COVID-19 Vaccine Acceptance/Hesitancy and Influence on Infection in Patients with Multiple Myeloma: A National-Wide Multicenter Survey in China (ASH 2023) - "ConclusionsVaccine hesitation is common in Chinese MM patients although inactivated COVID-19 vaccine only causes mild AEs...COVID-19 vaccination is not translated into less SARS-COV-2 infections, but does protect the elderly, obese or R/RMM patients from severe infections. Clinicians are suggested to encourage MM patients to receive COVID-19 vaccines for the sake of reducing severe infections and related mortality."

Clinical • Dermatology • Fatigue • Hematological Malignancies • Infectious Disease • Multiple Myeloma • Musculoskeletal Diseases • Musculoskeletal Pain • Obesity • Oncology • Orthopedics • Pain • Respiratory Diseases

Humoral Immune Response to Inactivated SARS-CoV-2 Vaccine in Populations With and Without Prior COVID-19 Infection: A Longitudinal Cohort Study. (PubMed, Viral Immunol) - "In conclusion, two doses effectively augmented antibody levels in naïve individuals, whereas a single dose may suffice to confer immune protection in COVID-19-recovered individuals. Antibody levels wane over time, necessitating further investigations into the durability of vaccine-mediated immune protection, evidence-based recommendations for preventive vaccination, and the formulation of immunization strategies tailored to distinct populations."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Prospective study of safety, immunogenicity, and efficacy of inactivated COVID-19 vaccine in tuberous sclerosis complex children on sirolimus. (PubMed, Hum Vaccin Immunother) - "The vaccine elicited attenuated immunogenicity in non-sirolimus group whereas vaccine combined with sirolimus might provide better protection against COVID-19. COVID-19 vaccination conferred good safety with mild breakthrough infections."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Humoral response dynamics following inactivated SARS-CoV-2 vaccination and their association with subsequent infection and symptoms in individuals with and without prior SARS-CoV-2 infection: evidence from Sichuan Province, China. (PubMed, Microbiol Spectr) - "This is the first finding from China that illustrates the dynamic characteristics of the immune response following inactivated COVID-19 vaccination over an extended observation period, including information on following infection and symptoms. These data are particularly valuable as no participants experienced COVID-19 infection during the vaccine cohort follow-ups, meaning their antibody levels solely reflect the intrinsic dynamic immune patterns triggered by the inactivated COVID-19 vaccines."

Journal • Fatigue • Infectious Disease • Musculoskeletal Pain • Novel Coronavirus Disease • Otorhinolaryngology • Pain • Respiratory Diseases

A Clinical Investigation Into the Effects of Severe Acute Respiratory Syndrome Coronavirus 2 Infection and Vaccination in Children With Acute Lymphoblastic Leukemia. (PubMed, J Med Virol) - "This study systematically evaluated the humoral immune responses and cytokine profiles of 259 pediatric participants, comprising both healthy individuals and patients with Acute Lymphoblastic Leukemia (ALL), following either administration of an inactivated SARS-CoV-2 vaccine or natural infection...Importantly, the JAK/STAT signaling pathway emerged as a key component in the immune response to SARS-CoV-2 among healthy subjects. These insights provide a scientific basis for the optimization of COVID-19 immunization strategies tailored to vulnerable pediatric groups."

Journal • Acute Lymphocytic Leukemia • Hematological Malignancies • Infectious Disease • Leukemia • Novel Coronavirus Disease • Oncology • Pediatrics • Respiratory Diseases

Essential Role of CD56dimNKG2C+ NK Cells Trained by SARS-CoV-2 Vaccines in Protecting Against COVID-19. (PubMed, Mol Ther) - "Here, we highlight how the natural-killer (NK) and macrophage (Mϕ) cells' response, primed by the inactivated COVID-19 vaccine, is crucial to preventing lung injury...Interestingly, our findings show a deficiency of these adaptive cells in older participants post-booster vaccination, leading to potentially inadequate protection. This study discusses the evaluation of vaccines at the innate immune level, which can contribute to the development of successful vaccines."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • B3GAT1 • CD8

COVID-19 inactivated booster vaccines elicit strong protection against SARS-CoV-2 wild-type and Omicron variant in patients with breast cancer. (PubMed, Front Med (Lausanne)) - "Blood samples from 211 breast cancer patients and 155 healthy controls were analyzed after one, two, or three doses of the inactivated SARS-CoV-2 vaccine...In particular, univariate and multivariate analyses revealed that the vaccination of breast cancer patients with CoronaVac resulted in significantly higher NAb inhibition rates against the SARS-CoV-2 wild-type virus than BBIBP-CorV...Vaccination-mediated NAb induction was affected by age, time > 6 months after vaccination, vaccine type, and cancer-targeted treatment. Therefore, the study results indicated an urgent need for caution and additional strategies to protect these patients."

Journal • Breast Cancer • Infectious Disease • Novel Coronavirus Disease • Oncology • Respiratory Diseases • Solid Tumor

Efficacy, safety, and immunogenicity of SARS-CoV-2 mRNA vaccine (Omicron BA.5) LVRNA012: a randomized, double-blind, placebo-controlled phase 3 trial. (PubMed, Front Immunol) - P=N/A | "This is a single-center, randomized, double-blind, placebo-controlled phase 3 clinical trial enrolling healthy adult participants (≥18 years) who had completed two or three doses of inactivated COVID-19 vaccines at least 6 months before, in Bengbu, Anhui province, China. The LVRNA012 mRNA vaccine is immunogenic, and shows robust efficacy in preventing COVID-19 during the omicron-predominate period. ClinicalTrials.gov, identifier NCT05745545."

Clinical • Journal • P3 data • P3 data • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Efficacy and safety of inactivated SARS-CoV-2 vaccination in COVID-19-associated pneumonia among patients with rheumatic and musculoskeletal diseases: A real-world retrospective observational study. (PubMed, Int J Rheum Dis) - "Inactivated COVID-19 vaccines were safe and effective in reducing the risk of COVID-19-associated pneumonia of RMD patients in China."

Journal • Observational data • Real-world • Real-world evidence • Retrospective data • Infectious Disease • Musculoskeletal Diseases • Novel Coronavirus Disease • Pneumonia • Respiratory Diseases

Evaluation of Binding and Neutralizing Antibodies for Inactivated SARS-CoV-2 Vaccine Immunization. (PubMed, Diseases) - "According to the threshold, we can quickly determine the positive and negative effects of the SARS-CoV-2 variant neutralizing antibody in individuals. These findings suggest that the S-IgG antibody is a better supplement to and confirmation of SARS-CoV-2 vaccine immunization."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Acceptance, safety, and immunogenicity of a booster dose of inactivated SARS-CoV-2 vaccine in patients with primary biliary cholangitis. (PubMed, Heliyon) - "Unvaccinated patients with PBC were more worried about the safety of the vaccine than those who were vaccinated (P = 0.004). As a result, this study fills the immunological assessment gap in patients with PBC who received inactivated COVID-19 vaccines."

Journal • Hepatology • Immunology • Infectious Disease • Novel Coronavirus Disease • Primary Biliary Cholangitis • Respiratory Diseases

Heterologous Booster Immunization Based on Inactivated SARS-CoV-2 Vaccine Enhances Humoral Immunity and Promotes BCR Repertoire Development. (PubMed, Vaccines (Basel)) - "Our research demonstrates that heterologous sequential immunization resulted in more immune responses displayed in the lymph node germinal center, which induced a greater number of antibody-secreting cells (ASCs), resulting in enhanced humoral and cellular immune responses and increased cross-protection against five variant strains. In further single B-cell analysis, the above findings were supported by the presence of unique B-cell receptor (BCR) repertoires and diversity in CDR3 sequence profiles elicited by a heterologous booster immunization strategy."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Immunogenicity assessment of elder hepatocellular carcinoma patients after inactivated whole-virion SARS-CoV-2 vaccination. (PubMed, Expert Rev Vaccines) - "This study aimed to investigate the efficacy and influencing factors of inactivated SARS-CoV-2 vaccine in elder HCC. Our findings highlight the booster effect and protective role of 3 dose. Our results could provide a theoretical foundation for informing decisions regarding SARS-CoV-2 vaccination in elder HCC."

Journal • Gastrointestinal Cancer • Hepatocellular Cancer • Infectious Disease • Novel Coronavirus Disease • Oncology • Respiratory Diseases • Solid Tumor

Safety and Immunogenicity Study of an Inactivated SARS-CoV-2 Vaccine for Preventing Against COVID-19 in People Aged ⩾60 Years (clinicaltrials.gov) - P1/2 | N=471 | Completed | Sponsor: Institute of Medical Biology, Chinese Academy of Medical Sciences | Enrolling by invitation ➔ Completed

Trial completion • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Safety and Immunogenicity Study of an Inactivated SARS-CoV-2 Vaccine for Preventing Against COVID-19 (clinicaltrials.gov) - P1/2 | N=942 | Completed | Sponsor: Institute of Medical Biology, Chinese Academy of Medical Sciences | Unknown status ➔ Completed

Trial completion • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

COVID-19 vaccine acceptance/hesitancy and influence on infection in patients with multiple myeloma: A national-wide multicenter survey in China (IMW 2023) - "Vaccine hesitation is common in Chinese MM patients although inactivated COVID-19 vaccine only causes mild AEs. Lower infection rate in MM patients is probably due to strict self-quarantine. COVID-19 vaccination is not translated into less SARS-COV-2 infections, but does protect the elderly, obese or R/RMM patients from severe infections."

Clinical • Bone Marrow Transplantation • Dermatology • Fatigue • Hematological Malignancies • Infectious Disease • Multiple Myeloma • Musculoskeletal Diseases • Musculoskeletal Pain • Novel Coronavirus Disease • Obesity • Oncology • Orthopedics • Pain • Respiratory Diseases • Transplantation

Antibody response to inactivated COVID-19 vaccine in patients with type 2 diabetes mellitus after the booster immunization. (PubMed, J Diabetes) - "Patients with T2DM showed impaired antibody responses after booster vaccination for more than 6 months. Decreased anti-BA.4/5 responses give rise to the possibility of breakthrough infections for both patients with T2DM and HCs."

Journal • Diabetes • Infectious Disease • Metabolic Disorders • Novel Coronavirus Disease • Respiratory Diseases • Type 2 Diabetes Mellitus • CD4 • CD8

Inactivated SARS-CoV-2 booster vaccine enhanced immune responses in patients with chronic liver diseases. (PubMed, Virol Sin) - "The effectiveness of the booster dose of inactivated SARS-CoV-2 vaccine in stimulating antibody response in CLD patients is unclear...CLD patients exhibited impaired immunologic responses to vaccination and weakened NAbs against BA.4/5, which hindered the protective effect of the booster shot against Omicron prevalence. Cellular immune responses should be further evaluated to determine the optimal vaccine regimen for CLD patients."

Journal • Hepatitis B • Hepatology • Infectious Disease • Inflammation • Novel Coronavirus Disease • Respiratory Diseases

A tale of two conditions: when people living with HIV meet three doses of inactivated COVID-19 vaccines. (PubMed, Front Immunol) - "Although a homogenous booster dose following two doses of the inactivated COVID-19 vaccine among PLWH could elicit higher nAb titers, reduce antibody decay, and maintain T cell responses even 6 months after vaccination, the overall immunogenicity of the booster dose was found to be lower among PLWH than among healthy controls. Further strategies are needed to improve immunogenicity to the inactivated COVID-19 vaccine among PLWH."

Journal • Human Immunodeficiency Virus • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • CD4 • CD8 • IFNG • TNFA

Antibody response to SARS-CoV-2 WT and Omicron BA.4/5 of inactivated COVID-19 vaccine in patients with lung cancer after second and booster immunization. (PubMed, J Hematol Oncol) - "Specifically, total B cells, CD4T cells and CD8T counts were correlated with the humoral response. These results should be taken into consideration for the elderly patients under treatment."

Journal • Infectious Disease • Lung Cancer • Novel Coronavirus Disease • Oncology • Respiratory Diseases • Solid Tumor

Omicron BA.1 breakthrough infections in inactivated COVID-19 vaccine recipients induced distinct pattern of antibody and T cell responses to different Omicron sublineages. (PubMed, Emerg Microbes Infect) - "The Omicron sublineages, especially for those emerged after BA.4/5 strain, evade the NAb responses induced by BA.1 breakthrough infection. It is urgent to optimize the vaccine immunogen design and formulations to SARS-CoV-2 variants."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Stable and durable antibody responses in SARS-recovered donors vaccinated with inactivated SARS-CoV-2 vaccine. (PubMed, J Med Virol) - "In SARS survivors, a single dose of inactivated SARS-CoV-2 vaccine provoked immune imprinting for the SARS antigen, providing protection against wild-type SARS-CoV-2 and the earlier variants of concern (VOCs) including Alpha, Beta, Gamma and Delta but not against Omicron subvariants. As such, it is important to evaluate the type and dosage of SARS-CoV-2 vaccine for SARS survivors."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Posner-Schlossman syndrome relapse following inactivated COVID-19 vaccination in China. (PubMed, Front Public Health) - "All the 12 patients were inoculated with inactivated COVID-19 vaccines developed by Sinopharm, China...Higher daily doses of corticosteroids, IOP-lowering drugs and ganciclovir were needed to maintain stable course, though the difference did not reach statistical significance. More frequent relapses and harder control of IOP were found in PSS relapse following COVID-19 vaccination. Ophthalmologists need to be aware of the group vulnerability and take precautions, though the pathogenesis is still under investigation."

Journal • Retrospective data • Infectious Disease • Novel Coronavirus Disease • Ocular Inflammation • Ophthalmology • Uveitis

Acceptance, safety and immunogenicity of a booster dose of inactivated SARS-CoV-2 vaccine in adults with tuberculosis. (PubMed, J Infect) - No abstract available

Journal • Infectious Disease • Novel Coronavirus Disease • Pulmonary Disease • Respiratory Diseases • Tuberculosis